Celgene (NASDAQ:CELG) has been given a $128.00 target price by stock analysts at Credit Suisse Group in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target points to a potential upside of 16.99% from the stock’s previous close.
Several other equities analysts also recently commented on the company. Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target on the stock. in a report on Tuesday, December 12th. Deutsche Bank began coverage on Celgene in a report on Tuesday, December 12th. They set a “hold” rating and a $114.00 price target on the stock. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Piper Jaffray Companies reiterated a “hold” rating on shares of Celgene in a report on Sunday, December 10th. Finally, Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $136.21.
Celgene (CELG) opened at $109.41 on Tuesday. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $86,140.36, a P/E ratio of 17.10, a P/E/G ratio of 0.84 and a beta of 1.78.
In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.95% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of CELG. Janus Henderson Group PLC lifted its position in Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the period. BlackRock Inc. lifted its holdings in shares of Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. bought a new position in shares of Celgene during the second quarter valued at $271,605,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Celgene by 1,489.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after acquiring an additional 1,787,052 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares during the period. 80.16% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by American Market News and is the sole property of of American Market News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/17/credit-suisse-group-analysts-give-celgene-celg-a-128-00-price-target.html.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
